强化免疫抑制治疗和单倍体移植治疗年轻重型再生障碍性贫血的比较

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (6): 759-764.

强化免疫抑制治疗和单倍体移植治疗年轻重型再生障碍性贫血的比较

陈苗^1＃, 吴亚妹^2＃, 周道斌¹, 段明辉¹, 庄俊玲¹, 韩冰^1*, 吴晓雄^2*

1.中国医学科学院北京协和医学院北京协和医院血液科, 北京 100730;
2.中国人民解放军总医院第四医学中心血液科, 北京 100048

收稿日期:2019-12-17 修回日期:2020-03-26 出版日期:2020-06-05 发布日期:2020-05-29
通讯作者: *hanbing_li@sina.com;xiongwuxiao@sohu.com
作者简介:^＃对本文有相同贡献
基金资助:
国家自然科学基金(81970106);中国医学科学院医学科学创新基金(2016-I2M-3-004)

Comparison of intensive immunosuppressive therapy with haploidentical transplantation for young severe aplastic anemia

CHEN Miao^1#, WU Ya-mei^2#, ZHOU Dao-bin¹, DUAN Ming-hui¹, ZHUANG Jun-ling¹, HAN Bing^1*, WU Xiao-xiong^2*

1. Department of Hematology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
2. Department of Hematology, the Fourth Medical Center of Chinese PLA General Hospital, Beijing 100048, China

Received:2019-12-17 Revised:2020-03-26 Online:2020-06-05 Published:2020-05-29
Contact: *hanbing_li@sina.com;xiongwuxiao@sohu.com

摘要/Abstract

摘要： 目的比较强化免疫抑制治疗(IST)与单倍体供者异基因造血干细胞移植(HID-HSCT)治疗年轻重型再生障碍性贫血(SAA)患者的疗效和转归。方法回顾性分析55例年龄14~30岁的SAA患者,其中IST组治疗29例,HID-HSCT组治疗26例。结果 IST组和HID-HSCT组完全缓解率分别为58.6%和84.6%(P＜0.05),总反应率分别为86.2%和84.6%。两组5年总生存率(IST组为77.9%±11.7%,HID-HSCT组为82.1%±8.4%)和无事件生存率(IST为67.6%±11.7%,HID-HSCT为69.2%±9.1%)差异无统计学意义。IST组复发率为3.4%,克隆转化率为13.8%;HID-HSCT组复发率和克隆转化率均为0%,但2~4级aGVHD和cGVHD的发生率分别为19.2%和15.4%。IST组的住院费用明显低于HID-HSCT组(中位费用16.8万元 vs 37.8万元, P ＜0.001)。结论 IST与HID-HSCT相比总反应率和生存率差异无统计学意义。鉴于费用低,IST仍然是无同胞供者的年轻SAA患者的合适选择。

关键词: 重型再生障碍性贫血, 强化免疫抑制治疗, 单倍体供者移植

Abstract: Objective A retrospective study was performed to compare intensive immunosuppressive therapy (IST) and haploidentical donor hematopoietic stem cell transplantation (HID-HSCT) for young patients with severe aplastic anaemia(SAA). Methods Fifty-five SAA patients aged 14-30 years were included. The patients were treated with anti-thymocyte immunoglobulin(ATG) combined with cyclosporine A(CsA)(29 cases, IST group) or HID-HSCT(26 cases, HID-HSCT group). Results The complete response(CR) rates in the IST and HID-HSCT groups were 58.6% vs 84.6%(P=0.034), and the overall response(OR) rates were 86.2% vs 84.6%. No significant difference was found in estimated 5-year overall survival(IST 77.9%±11.7% vs HID-HSCT 82.1%±8.4%) and event-free survival(IST 67.6%±11.7% vs HID-HSCT 69.2%±9.1%). The relapse rate of the IST group was 3.4%, and the clonal transformation rate was 13.8%. In HID-HSCT group, the relapse and clonal transformation rates were both 0%, and the incidence rates of grades 2-4 aGVHD and cGVHD were 19.2% and 15.4% respectively. The hospitalization expenses were significantly less in the IST group than in that of HID-HSCT group(median 168 000 yuan vs 378 000 yuan, P＜0.001). Conclusions IST shows similar OR, OS and EFS but much less expense comparing with that of HID-HSCT. IST remains an appropriate choice for young SAA patients without sibling donors.

Key words: aplastic anemia, intensive immunosuppressive therapy, donor transplantation

中图分类号:

R551.3

陈苗, 吴亚妹, 周道斌, 段明辉, 庄俊玲, 韩冰, 吴晓雄. 强化免疫抑制治疗和单倍体移植治疗年轻重型再生障碍性贫血的比较[J]. 基础医学与临床, 2020, 40(6): 759-764.

CHEN Miao, WU Ya-mei, ZHOU Dao-bin, DUAN Ming-hui, ZHUANG Jun-ling, HAN Bing, WU Xiao-xiong. Comparison of intensive immunosuppressive therapy with haploidentical transplantation for young severe aplastic anemia[J]. Basic & Clinical Medicine, 2020, 40(6): 759-764.

参考文献

[1]Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the severe aplastic anemia working party of the European group for blood and marrow transplantation[J]. Haematol,2014,99: 1574-1581.
[2]Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant[J]. Br J Haematol,2015,169: 565-573.
[3]Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy[J]. Haematol,2014,99: 1784-1791.
[4]Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol,2016,172: 187-207.
[5]Xu LP, Xu ZL, Wang FR, et al. Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia[J]. Bone Marrow Transplant,2018,53:188-192.
[6]Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant[J]. J Hematol Oncol,2017,10: 25.
[7]Cheng Y, Xu Z, Zhang Y, et al. First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy[J]. Clin Transplant,2018,32(2):10.1111/ctr.13179.
[8]Xu ZL, Zhou M, Jia JS, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia[J]. Bone Marrow Transplant,2019,54:1319-1326.
[9]Camitta BM, Rappeport JM, Parkman R, et al. Selection of patients for bone marrow transplantation in severe aplastic anemia[J]. Blood,1975,45: 355-363.
[10]Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation(BMT) versus immunosuppression for the treatment of severe aplastic anaemia(SAA): a report of the EBMT SAA working party[J]. Br J Haematol,1988,70: 177-182.
[11]Yamei W, Rongmu L, Yongbin C, et al. Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning[J]. Oncotarget,2017,8: 83817-83830.
[12]Chang YJ, Zhao XY, Xu LP, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets[J]. J Hematol Oncol,2015,8: 84.
[13]Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia[J]. Br J Haematol,2009,147: 43-70.
[14]Chen M, Liu C, Zhuang J, et al. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia[J]. Eur J Haematol,2016,96: 291-296.